Nutranomics provides update on GenEpic prostate cancer human clinical study

Nutranomics, Inc. (OTCBB: NNRX) (OTCQB: NNRX) ("Nutranomics" or the "Company") is pleased to provide this update regarding the GenEpic™ prostate cancer human clinical study that is currently underway. Nutranomics has previously announced a non-binding Letter of Intent with Genesar Nutraceuticals, LLC ("Genesar") with the intent of completing a licencing agreement to market and distribute GenEpic™ globally.

"We are very pleased to report that our science and legal teams have recently been able to conduct a full due diligence review of the most recent progress and data from the current IRB reviewed GenEpic™ human clinical study being conducted at OH Research Group in Salt Lake City, Utah," stated Nutranomics' CEO Dr. Tracy K. Gibbs. "The one-year study is now in its 11^th month and we are all very encouraged by the positive results. We look forward to the conclusion of the current study within the next 60 days and completing the planned acquisition of the GenEpic™ distribution rights."

The GenEpic™ human clinical study on prostate cancer treatment and recovery has been reviewed by an Institutional Review Board (IRB). The IRB reviews plans for all research involving human subjects. The Food and Drug Administration (FDA) and the Office for Human Research Protections (OHRP) (part of the National Institutes of Health) set the guidelines and regulations governing human subjects research and IRBs.

Dr. Gibbs concluded, "Because GenEpic™ is intended to act as an ATP inhibitor, we are hopeful that the study will show that it is effective for treating prostate cancer, and that it could also be effective to treat many other types of rapidly growing cancers. Once this study is complete, we anticipate starting new research on breast cancer treatment and potentially other forms of the disease."

GenEpic™ is a natural therapeutic formula containing 70 vitamins and minerals, 32 herbs, and 16 enzymes and phytonutrients, and formulated by a respected team of five scientists and natural medicine experts, including Dr. Gibbs.  GenEpic™ is currently the subject of an IRB reviewed human clinical study on prostate cancer treatment and recovery that is expected to be completed within the next 60 days.

The potential completion of a GenEpic™ distribution licence is subject to the parties entering into a definitive agreement.  There can be no assurance that any transaction will be completed as proposed or at all.